These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 27050696)

  • 21. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia.
    Sato A; Takeda A
    J Dermatol; 2012 Jan; 39(1):27-32. PubMed ID: 21980923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia.
    Boersma IH; Oranje AP; Grimalt R; Iorizzo M; Piraccini BM; Verdonschot EH
    Indian J Dermatol Venereol Leprol; 2014; 80(6):521-5. PubMed ID: 25382509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Finasteride adverse effects: An update].
    Carreño-Orellana N; Moll-Manzur C; Carrasco-Zuber JE; Álvarez-Véliz S; Berroeta-Mauriziano D; Porras-Kusmanic N
    Rev Med Chil; 2016 Dec; 144(12):1584-1590. PubMed ID: 28393993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases.
    Wu M; Yu Q; Li Q
    Oncotarget; 2016 Dec; 7(50):82074-82084. PubMed ID: 27738338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgenetic alopecia; drug safety and therapeutic strategies.
    Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
    Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
    Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
    Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
    Lee S; Lee YB; Choe SJ; Lee WS
    Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5α-Reductase inhibitors in androgenetic alopecia.
    Yim E; Nole KL; Tosti A
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):493-8. PubMed ID: 25268732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-finasteride syndrome: a surmountable challenge for clinicians.
    Traish AM
    Fertil Steril; 2020 Jan; 113(1):21-50. PubMed ID: 32033719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride.
    Jung JY; Yeon JH; Choi JW; Kwon SH; Kim BJ; Youn SW; Park KC; Huh CH
    Int J Dermatol; 2014 Nov; 53(11):1351-7. PubMed ID: 24898559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review.
    Fertig RM; Gamret AC; Darwin E; Gaudi S
    Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controversies in the treatment of androgenetic alopecia: The history of finasteride.
    Andy G; John M; Mirna S; Rachita D; Michael K; Maja K; Aseem S; Zeljana B
    Dermatol Ther; 2019 Mar; 32(2):e12647. PubMed ID: 30253001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness.
    Sinclair R; Patel M; Dawson TL; Yazdabadi A; Yip L; Perez A; Rufaut NW
    Br J Dermatol; 2011 Dec; 165 Suppl 3():12-8. PubMed ID: 22171680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis.
    Gupta AK; Mays RR; Dotzert MS; Versteeg SG; Shear NH; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2112-2125. PubMed ID: 29797431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms.
    Ganzer CA; Jacobs AR; Iqbal F
    Am J Mens Health; 2015 May; 9(3):222-8. PubMed ID: 24928450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atypical post-finasteride syndrome: A pharmacological riddle.
    Gupta AK; Sharma N; Shukla P
    Indian J Pharmacol; 2016; 48(3):316-7. PubMed ID: 27298504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride.
    Gupta AK; Charrette A
    J Dermatolog Treat; 2014 Apr; 25(2):156-61. PubMed ID: 23768246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss).
    Shapiro J; Kaufman KD
    J Investig Dermatol Symp Proc; 2003 Jun; 8(1):20-3. PubMed ID: 12894990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia.
    Chiriacò G; Cauci S; Mazzon G; Trombetta C
    Andrology; 2016 Mar; 4(2):245-50. PubMed ID: 26763726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia.
    Tsunemi Y; Irisawa R; Yoshiie H; Brotherton B; Ito H; Tsuboi R; Kawashima M; Manyak M;
    J Dermatol; 2016 Sep; 43(9):1051-8. PubMed ID: 26893187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.